- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05326750
Neuroestimulação não invasiva como ferramenta de diagnóstico e tratamento de doenças neurodegenerativas
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Eino Solje, MD, PhD
- Número de telefone: +358 17 713 311
- E-mail: eino.solje@uef.fi
Locais de estudo
-
-
-
Kuopio, Finlândia
- Recrutamento
- Kuopio University Hospital
-
Contato:
- Eino Solje
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Mild Cognitive Impairment due to Alzheimer's disease
- Dementia with Lewy Bodies
- Frontotemporal dementia
- Idiopathic normal pressure hydrocephalus (iNPH)
Exclusion Criteria:
- History of seizures
- Pregnancy
- Metal implants in the head (except dental fillings)
- Electronic implants (i.e. pace-maker, implanted medical pump)
- Age <18 years
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Real tACS
Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus) |
Single session of gamma tACS (40 Hz) over the superior parietal cortex |
|
Comparador de Placebo: Sham tACS
Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus) |
Single session of gamma tACS (40 Hz) over the superior parietal cortex |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes in Rey Auditory Verbal Learning Test score
Prazo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes. The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance). |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in Rey Auditory Verbal Learning Test, recognition
Prazo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance). |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in orientation to time and place (MMSE questions 1-10)
Prazo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance). |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
|
Changes in Trail Making A & B tests
Prazo: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
TMT A & B tests. Time to perform set is recorded. |
Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in INECO Frontal Screening test
Prazo: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance) |
Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
|
|
Changes in phonemic fluency
Prazo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute. |
Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in SAI measurements
Prazo: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in SICI measurements
Prazo: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in ICF measurements
Prazo: Baseline (immediately before the intervention), immediately after the last intervention
|
By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission. |
Baseline (immediately before the intervention), immediately after the last intervention
|
|
Change in modified Frontal Behavioral Inventory (FBI-mod) score
Prazo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
The modified Frontal Behavioral Inventory (FBI-mod) is used to assess behavioral symptoms associated with frontotemporal dysfunction. The questionnaire evaluates changes in behavioral and personality features. Higher scores indicate a greater severity of behavioral symptoms. |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
|
Change in Neuropsychiatric Inventory (NPI) score
Prazo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
The Neuropsychiatric Inventory (NPI) is used to assess neuropsychiatric symptoms, including their frequency and severity. Higher total scores indicate a greater burden of neuropsychiatric symptoms. |
Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Eino Solje, MD, PhD, Kuopio University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Sinucleinopatias
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Doenças Metabólicas
- Distúrbios Neurocognitivos
- Demência
- Tauopatias
- Doenças Neurodegenerativas
- Distúrbios do Movimento
- Distúrbios parkinsonianos
- Doenças dos Gânglios da Base
- Proteinopatias TDP-43
- Deficiências de Proteostase
- Degeneração Lobar Frontotemporal
- Doenças Nutricionais e Metabólicas
- Doença de Alzheimer
- Demência frontotemporal
- Doença de corpos de Lewy
Outros números de identificação do estudo
- KUH5772859
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Pseudonymized data upon request, according to Finnish national and EU GDPR regulations
Prazo de Compartilhamento de IPD
Data will be shared after the study completion indefinitely.
Critérios de acesso de compartilhamento IPD
Reasonable request
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .